Skip to main content

Table 1 2-fuoryl-LIGRLO-amide (2fly) concentration-response curves of mesenteric arteries from saline- and angiotensin II-treated C57 mice.

From: Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice

Treatment

n

-log EC50

(M)

Emax

(%)

Hill slope

n

-log EC50

(M) a d

Emax

(%) b d

Hill slope c f

 

Saline

Angiotensin II

controls

48

8.3(0.1)

97(1)

2.1(0.1)

52

8.1(0.1)

96(1)

1.8(0.1)

L-NAME

12

7.8(0.2)i

90(2)j

1.9(0.6)j

24

7.8(0.1) j

85(2)i

1.3(0.2)

indomethacin

12

8.4(0.1)

96(1)

2.1(0.5)

17

7.9(0.1)h

93(1)

1.5(0.2)

L-NAME + indomethacin

10

8.0(0.1)

90(2)k

1.2(0.3)

18

7.4(0.1)g i

81(4)g i

1.3(0.2)

NS398 3 μM

5

8.2(0.4)

92(4)

2.3(0.3)

7

7.9(0.1)

93(2)

4.7(1.6)h i

FR122047

12

8.3(0.1)

96(1)

2.0(0.3)

15

7.8(0.1)h k

91(2)

1.7(0.3)

NS398 + FR122047

5

8.0(0.2)

92(2)

0.9(0.1)

8

8.0(0.2)

94(2)

2.4(0.4)

CAY10441

7

8.3(0.2)

96(2)

1.8(0.3)

7

8.0(0.1)

96(1)

2.2(0.4)

AH6809 + L798106 + L161982

6

8.5(0.3)

97(1)

1.5(0.3)

6

8.0(0.1)

96(1)

2.2(0.4)

SQ29548

4

8.5(0.2)

96(1)

0.8(0.2)

6

7.9(0.2)

93(2)

2.0(0.4)

NS398 0.3 μM

7

8.1(0.1)

98(1)

2.1(0.3)

6

7.8(0.1)

95(1)

2.4(0.6)

  1. Values are mean(SE), n = number of mice. Variables were determined by curve fitting data points from cumulative drug concentration-responses relationships to a four parameter logistic function. Treatments of arteries included antagonists of COX-1 (1 μM FR122047), COX-2 (0.3, 3 μM NS398), COX-1/2 (10μM indomethacin), NOS (100 μM L-NAME), prostaglandin E2receptors (1 μM AH6809, 1 μM L798106, 0.1 μM L161982), prostaglandin I2receptor (0.1 μM CAY10441) and thromboxane A2receptor (1 μM SQ29548). Comparisons were made by two-way ANOVA (pump × artery treatment) [aP < 0.0001, bP < 0.01, and cP < 0.05, effect of pump treatment, dP < 0.0001, and eP < 0.0005, effect of artery treatment, fP < 0.01, interaction between pump and treatment] followed by Bonferroni post hoc tests: gP < 0.01, and hP < 0.05, compared to same inhibitor treatment in saline pump group [horizontal]; iP < 0.001, jP < 0.01, and kP < 0.05, controls compared to inhibitor within same pump treatment [vertical].
  2. C57, C57BL/6J; Emax, maximum relaxation response where 100% is complete reversal of contraction.